pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 3.53k
3.53k
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
12327T | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
12327T | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
9090K | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9090K | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9090K | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9090K | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12430F | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12430F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12430F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12430F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12430F | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12430F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12430F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12430F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8638P | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8638P | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11515C | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9472 | true | STREAMLINED | Private | 3,531 | 2,025 | JANUARY |
11515C | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9472 | true | STREAMLINED | Private | 3,531 | 2,025 | JANUARY |
11675L | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11675L | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12624K | upadacitinib | Rinvoq | Tablet 15 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12624K | upadacitinib | Rinvoq | Tablet 15 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12624K | upadacitinib | Rinvoq | Tablet 15 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12624K | upadacitinib | Rinvoq | Tablet 15 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
13757C | tofacitinib | Xeljanz | Tablet 5 mg | juvenile idiopathic arthritis | Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
9663N | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
11361Y | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11361Y | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11361Y | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11361Y | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11516D | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11516D | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11538G | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11538G | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11538G | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11538G | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12802T | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
12802T | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
10511F | tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
10511F | tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
13299Y | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | 14093 | true | STREAMLINED | Public | 3,531 | 2,025 | JANUARY |
11204Q | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8741C | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8741C | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8741C | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8741C | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8741C | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8741C | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8741C | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8741C | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11693K | abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11693K | abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11693K | abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11693K | abatacept | Orencia ClickJect | Injection 125 mg in 1 mL single dose autoinjector | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
6496X | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
6496X | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
6496X | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
6496X | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |